Tempus AI, Inc.

About Tempus AI, Inc.

Financials

Dated, source-cited figures. Estimates are marked.

Products by Tempus AI, Inc.

All products by Tempus AI, Inc. reviewed by our AI panel of experts.

Tempus AIAI Healthcare

Precision medicine data and AI platform for oncology and healthcare

Free6.9/10

Competitive Landscape

Who Tempus AI, Inc. competes with, and how they differ.

C

Caris Life Sciences

Named in the Tempus FY2025 Form 10-K as a primary competitor for its marketed precision oncology tests. Caris (Nasdaq: CAI, Irving, Texas) runs its own tissue and liquid molecular profiling labs and licenses AI-derived molecular datasets to pharma, the closest structural match to the Tempus diagnostics-plus-data model; it listed on Nasdaq in June 2025, a year after Tempus.

Flatiron Health8.2/10

Named in the Tempus FY2025 Form 10-K as a main competitor for the Data and applications product line. Flatiron, a Roche subsidiary, assembles oncology real-world datasets from its own OncoEMR practice software and sells them to life-sciences customers, whereas Tempus generates its data as a byproduct of running the sequencing lab itself.

1 product reviewed on TopReviewed

PathAI7.9/10

Competes head-on with Paige, the digital-pathology company Tempus acquired in August 2025 for $101.5 million. PathAI sells AI pathology algorithms and its AISight image-management platform to pharma and laboratories as software, while Tempus embeds pathology models in a lab it operates and bills through diagnostics.

1 product reviewed on TopReviewed

SOPHiA GENETICS7.5/10

Sells its SOPHiA DDM genomic-analysis platform as software to hospitals and laboratories that run their own sequencers, a decentralized model. Tempus centralizes sequencing in its own CLIA labs and monetizes the resulting multimodal dataset through pharma data licensing, so the two compete for genomic interpretation budgets from opposite directions.

1 product reviewed on TopReviewed

K

Komodo Health7.6/10

Overlaps the Tempus Data and applications business in selling real-world evidence to life-sciences companies, but the Komodo Healthcare Map is built from de-identified claims and encounter data across all disease areas rather than from clinical-genomic records generated in an oncology laboratory.

1 product reviewed on TopReviewed

Company Timeline

Key milestones in Tempus AI, Inc.'s history, with sources.

1. Jul 20, 2026Acquisition

   Agreement to acquire Personalis for about $1.5B

   Tempus agreed to acquire Nasdaq-listed Personalis at $16.25 per share, a total enterprise value of about $1.5 billion net of the stake Tempus already held, bringing the NeXT Personal minimal residual disease test in-house. Consideration is structured as an all-stock transaction with an option for Tempus to pay up to 50 percent in cash.

   sec.gov
2. Jun 30, 2026Milestone

   First profitable quarter: $5.6M net income in Q2 2026

   For the quarter ended June 30, 2026 Tempus reported net income of $5.6 million on revenue of $382.5 million, its first quarterly profit since the June 2024 IPO and a reversal of the $42.8 million net loss recorded in the same quarter of 2025.

   sec.gov
3. May 12, 2026Funding

   $460M of 0.00% convertible senior notes; Ares credit facility repaid

   Tempus closed a $460.0 million private offering of 0.00% convertible senior notes due 2032, including the initial purchasers $60 million option exercised in full, and used part of the proceeds to repay in full and terminate the 2022 Ares Capital credit agreement.

   sec.gov
4. Aug 22, 2025Acquisition

   Acquisition of digital pathology company Paige.AI

   Tempus completed the acquisition of Paige.AI, a digital-pathology AI company, for $101.5 million: $3.0 million in cash plus 1,256,977 Class A shares valued at $80.52 each. The transaction produced $141.1 million of goodwill.

   sec.gov
5. Jul 3, 2025Funding

   $750M of 0.75% convertible senior notes due 2030

   Tempus closed a private offering of $750.0 million aggregate principal amount of 0.75% convertible senior notes due 2030, including full exercise of the initial purchasers over-allotment option, and amended its Ares Capital credit agreement in connection with the offering.

   sec.gov
6. April 2025Partnership

   AstraZeneca and Pathos AI agreements to build an oncology foundation model

   In April 2025 Tempus signed agreements with AstraZeneca and Pathos AI to develop a large multimodal foundation model in oncology. AstraZeneca pays Tempus a $35 million fee, and Pathos pays $200 million in data-license fees over three years, including a $50 million upfront payment made in April 2025.

   sec.gov
7. Mar 11, 2025Acquisition

   Acquisition of clinical-trial matching company Deep 6 AI

   Tempus acquired Deep 6 AI, whose software mines structured and unstructured electronic medical record data to match patients to clinical trials, for $17.4 million: $4.3 million in cash and $13.1 million in Class A common stock.

   sec.gov
8. Feb 3, 2025Acquisition

   Ambry Genetics acquisition closes for $692.3M

   Tempus completed its purchase of hereditary-cancer testing company Ambry Genetics from REALM IDx, a subsidiary of Konica Minolta, under a securities purchase agreement signed November 4, 2024. Total acquisition price was $692.3 million: $394.3 million in cash plus 4,843,136 Class A shares valued at $61.54 each.

   sec.gov
9. Jul 18, 2024Partnership

   SB Tempus Corp. joint venture with SoftBank closes in Japan

   Tempus and SoftBank Group Corp. closed the joint venture agreement signed May 18, 2024, forming SB Tempus Corp. Each side contributed 15 billion yen (about $95.2 million) for 50 percent of the venture, which performs clinical sequencing, organizes patient data and builds a real-world data business in Japan.

   sec.gov
10. Jun 13, 2024Milestone

    Nasdaq IPO priced at $37.00 per share, raising $410.7M

    Tempus priced its initial public offering of 11,100,000 Class A shares at $37.00 per share for gross proceeds of $410.7 million and listed on the Nasdaq Global Select Market under the ticker TEM. The prospectus is dated June 13, 2024, with delivery of shares expected June 17, 2024.

    sec.gov
11. Apr 30, 2024Funding

    Series G-5 preferred round: $200M from a SoftBank-affiliated investor

    Six weeks before its IPO, Tempus sold 3,489,981 shares of Series G-5 convertible preferred stock at $57.3069 per share to an investor affiliated with SoftBank Group Corp., for aggregate proceeds of approximately $200.0 million.

    sec.gov
12. 2015Founded

    Tempus founded in Chicago by Eric Lefkofsky

    Tempus was founded in late 2015 by Eric Lefkofsky, who serves as Chief Executive Officer, Founder and Chairman, to apply AI to clinical and molecular data for precision medicine. Headquarters are at 600 West Chicago Avenue, Chicago, Illinois.

    sec.gov